|
| 1. |
Yokoyama H, Araki SI, Yamazaki K, Kawai K, Shirabe SI, Oishi M, Kanatsuka A, Yagi N, Kabata D, Shintani A, Maegawa H; JDDM study group. Trends in glycemic control in patients with insulin therapy compared with non-insulin or no drugs in type 2 diabetes in Japan: a long-term view of real-world treatment between 2002 and 2018 (JDDM 66). BMJ Open Diabetes Res Care 2022;10:e002727. |
| 2. |
横山宏樹 腎疾患を有する糖尿病・代謝疾患の留意点 糖尿病・内分泌代謝科 2022;54:134-139 |
| 3. |
横山宏樹、荒木信一、前川聡 わが国における糖尿病患者の兆候の推移 腎臓内科 2022;15:18-24 |
| 4. |
横山宏樹 日本における糖尿病および腎症の現状と予後（JDDM研究の結果より） 糖尿病合併症 2022;36:116-122 |
| 5. |
Nomoto H, Oba-Yamamoto C, Takahashi Y, Takeuchi J, Nagai S, Yokoyama H, Taneda S, Kurihara Y, Aoki S, Kameda H, Cho KY, Nakamura A, Atsumi T, Miyoshi H. Effects of Switching from Liraglutide or Dulaglutide to Subcutaneous Semaglutide on Glucose Metabolism and Treatment Satisfaction in Patients with Type 2 Diabetes: Protocol for a Multicenter, Prospective, Randomized, Open-Label, Blinded-Endpoint, Parallel-Group Comparison Study (The SWITCH-SEMA 1 Study). Diabetes Ther 2021;12:955-964. |
| 6. |
Cho KY, Nomoto H, Nakamura A, Kawata S, Sugawara H, Takeuchi J, Nagai S, Omori K, Tsuchida K, Miya A, Shigesawa I, Tsuchida K, Yanagiya S, Kameda H, Yokoyama H, Taneda S, Kurihara Y, Aoki S, Nishimoto N, Atsumi T, Miyoshi H. Improved time in range and postprandial hyperglycemia with canagliflozin in combination with teneligliptin: Secondary analyses of the CALMER study. J Diabetes Investig 2021;12:1417-1424. |
| 7. |
Miya A, Nakamura A, Cho KY, Kawata S, Nomoto H, Nagai S, Sugawara H, Taneda S, Tsuchida K, Omori K, Yokoyama H, Takeuchi J, Aoki S, Kurihara Y, Atsumi T, Miyoshi H. Impact of endogenous insulin secretion on the improvement of glucose variability in Japanese patients with type 2 diabetes treated with canagliflozin plus teneligliptin. J Diabetes Investig 2021;12:1395-1399. |
| 8. |
Yagi N, Komiya I, Arai K, Oishi M, Fukumoto Y, Shirabe S, Yokoyama H, Yamazaki K, Sugimoto H, Maegawa H. Japan Diabetes Clinical Data Management Study Group (JDDM study group). Current status of oral antidiabetic drug prescribing patterns based on the body mass index for Japanese type 2 diabetes mellitus patients and yearly changes in diabetologists' prescribing patterns from 2002 to 2019 (JDDM61). J Diabetes Investig 2021. Online ahead of print. |
| 9. |
Takeda Y, Fujihara K, Nedachi R, Ikeda I, Morikawa SY, Hatta M, Horikawa C, Kato M, Kato N, Yokoyama H, Kurihara Y, Miyazawa K, Maegawa H, Sone H. Comparing Associations of Dietary Energy Density and Energy Intake, Macronutrients with Obesity in Patients with Type 2 Diabetes (JDDM 63). Nutrients 2021;13:3167. |
| 10. |
Katakami N, Mita T, Yoshii H, Shiraiwa T, Yasuda T, Okada Y, Torimoto K, Umayahara Y, Kaneto H, Osonoi T, Yamamoto T, Kuribayashi N, Maeda K, Yokoyama H, Kosugi K, Ohtoshi K, Hayashi I, Sumitani S, Tsugawa M, Ryomoto K, Taki H, Nakamura T, Kawashima S, Sato Y, Watada H, Shimomura I; UTOPIA study investigators. The Influence of Tofogliflozin on Treatment-Related Quality of Life in Patients with Type 2 Diabetes Mellitus. Diabetes Ther 2021;12:2499-2515. |
| 11. |
Yamamoto T, Tanaka M, Kuribayashi N, Okuguchi F, Isotani H, Iwamoto M, Sugimoto H, Nakagawa O, Minabe M, Fuchida S, Mochida Y, Yokoyama H. Low education is associated with poor periodontal status in patients with type 2 diabetes mellitus: A cross-sectional study. Clin Exp Dent Res 2021;7:419-428. |
| 12. |
横山 宏樹, 荒木 信一, 前川 聡: 日本人DKDの臨床像：JDDM研究を中心として． 編 門脇孝, 山内敏正, 診断と治療社, 糖尿病学2021 p. 147-155, 2021． |
| 13. |
Yokoyama H, Araki S, Kawai K, Yamazaki K, Shirabe S, Sugimoto H, Minami M, Miyazawa I, Maegawa H for the JDDM Study Group. The prognosis of patients with type 2 diabetes and nonalbuminuric diabetic kidney disease is not always poor: implication of the effects of coexisting macrovascular complications (JDDM54). Diabetes Care 2020;43:1102-1110. |
| 14. |
Yokoyama H, Shiraiwa T, Takahara M, Iwamoto M, Kuribayashi N, Nomura T, Yamada M, Sone H, Araki S. Applications of physical performance measures to routine diabetes care for frailty prevention concept: fundamental data with grip strength, gait speed, timed chair stand speed, standing balance, and knee extension strength. BMJ Open Diabetes Research and Care 2020;8:e001562. |
| 15. |
Yokoyama H. Commentary: Incidence of severe urinary tract infections not increased by initiating sodium-glucose cotransporter 2 inhibitors. J Diabetes Investig 2020;11:530-531. |
| 16. |
Horikawa C, Hatta M, Morikawa SY, Takeda Y, Takeuchi M, Fujihara K, Kato N, Yokoyama H, Kurihara Y, Iwasaki K, Tanaka S, Maegawa H, Sone H. Family Support for Medical Nutritional Therapy and Dietary Intake among Japanese with Type 2 Diabetes (JDDM 56). Nutrients 2020;12:2649. |
| 17. |
Cho KY, Nomoto H, Nakamura A, Kawata S, Sugawara H, Takeuchi J, Nagai S, Tsuchida K, Omori K, Yokoyama H, Manda N, Kurihara Y, Aoki S, Atsumi T, Miyoshi H. Favourable effect of the sodium-glucose co-transporter-2 inhibitor canagliflozin plus the dipeptidyl peptidase-4 inhibitor teneligliptin in combination on glycaemic fluctuation: An open-label, prospective, randomized, parallel-group comparison trial (the CALMER study). Diabetes Obes Metab 2020;22:458-462. |
| 18. |
横山 宏樹, 荒木 信一, 前川 聡: JDDM-日本人2型糖尿病の管理状況の動向とDKDから見た予後．糖尿病の最新治療 Current Diabetology vol.11 No.2, p. 82-88 , 2020． |
| 19. |
Yokoyama H, Tsuji T, Hayashi S, Kabata D, Shintani A. Factors associated with diabetic polyneuropathy-related sensory symptoms and signs in patients with polyneuropathy: A cross-sectional Japanese study (JDDM 52) using a non-linear model. J Diabetes Investig 2020; 11: 450-457. |
| 20. |
Tanaka M, Yamamoto T, Kuribayashi N, Okuguchi F, Isotani H, Iwamoto M, Sugimoto H, Nakagawa O, Suzuki D, Abe K, Watanabe N, Minabe M, Fuchida S, Yokoyama H. Association of urinary albumin excretion with periodontal parameters in patients with type 2 diabetes mellitus, a cross-sectional study. Diabetol Int 2019;11:121-128. |
| 21. |
Yokoyama H, Yamamoto T, Tanaka M, Kudo C, Hidaka K, Kuribayashi N, Minabe M. Albuminuria, C-reactive protein, and socioeconomic factors are associated with periodontal status in subjects with type 2 diabetes. Diabetol Int 2019;10:250-259. |
| 22. |
Yokoyama H, Nagao A, Watanabe S, Honjo J. Incidence and risk of vaginal candidiasis associated with sodium-glucose cotransporter 2 inhibitors in real-world practice for women with type 2 diabetes. J Diabetes Investig 2019;10:439-445. |
| 23. |
Hatta M, Fujihara K, Morikawa SY, Takeda Y, Ishii D, Horikawa C, Kato M, Yokoyama H, Kurihara Y, Iwasaki K, Miyazawa K, Yamazaki K, Tanaka S, Maegawa H, Sone H. Combined Effects of Energy Intake and Physical Activity on Obesity in Japanese Patients with Type 2 Diabetes (JDDM 50). A Cross-Sectional Study. Diabetes Ther 2019;10:1133-1138. |
| 24. |
Yokoyama H, Araki S, Kawai K, Hirao K, Kurihara Y, Seino H, Takamura H, Sugimoto H, Okada A, Maegawa H for the Japan Diabetes Clinical Data Management study group. Current status of achieving blood pressure target and its clinical correlates in Japanese type 2 diabetes (JDDM45). J Diabetes Investig 2018;9: 594-601. |
| 25. |
Yokoyama H, Araki S, Kawai K, Yamazaki K, Tomonaga O, Shirabe S, Maegawa H, for the JDDM study group. Declining trends of diabetic nephropathy, retinopathy and neuropathy with improving diabetes care indicators in Japanese patients with type 2 and type 1 diabetes (JDDM46). BMJ Open Diabetes Research and Care 2018;6:e000521. |
| 26. |
横山 宏樹： 包括的治療による合併症予防：糖尿病合併症．診断と治療のABC 124, 古屋大祐 企画．大阪, 最新医学社, p.287-297 , 2017. |
| 27. |
横山 宏樹： JDDM・横山研究からみた日本人糖尿病の管理・予後に関する特異性： 糖尿病の日本人特異性．月刊糖尿病vol. 9, No.6, p. 72-83 , 2017. |
| 28. |
Fujihara K, Igarashi R, Matsunaga S, Matsubayashi Y, Yamada T, Yokoyama H, Tanaka S, Shimano H, Maegawa H, Yamazaki K, Kawai K, Sone H. Comparison of baseline characteristics and clinical course in Japanese patients with type 2 diabetes among whom different types of oral hypoglycemic agents were chosen by diabetes specialists as initial monotherapy (JDDM 42). Medicine (Baltimore). 2017;96:e6122. |
| 29. |
Yokoyama H, Oishi M, Takamura H, Yamasaki K, Shirabe S, Uchida D, Sugimoto H, Kurihara Y, Araki S, Maegawa H. Large-scale survey of rates of achieving targets for blood glucose, blood pressure, and lipids and prevalence of complications in type 2 diabetes (JDDM40). BMJ Open Diabetes Research and Care 2016;4:e000294. |
| 30. |
Otani T, Yokoyama H, Ohashi Y, Uchigata Y. Improved incidence of end-stage renal disease of type 1 diabetes in Japan, from a hospital-based survey. BMJ Open Diabetes Research and Care 2016;4:e000177. |
| 31. |
Mita T, Katakami N, Shiraiwa T, Yoshii H, Onuma T, Kuribayashi N, Osonoi T, Kaneto H, Kosugi K, Umayahara Y, Yamamoto T, Matsumoto K, Yokoyama H, Tsugawa M, Gosho M, Shimomura I, Watada H. Collaborators on the sitagliptin preventive study of intima-media thickness Evaluation (SPIKE) trial. Sitagliptin attenuates the progression of carotid intima-media thickening in insulin-treated patients with type 2 diabetes. The sitagliptin preventive study of intima-media thickness evaluation (SPIKE). A randomized controlled trial. Diabetes Care 2016;39:455-464. |
| 32. |
Takahara M, Shiraiwa T, Abe K, Ishimaru Y，Iwamoto M，Shimizu M，Tomonaga O，Yokoyama H. Variations in the associations of taste-related words with foods in diabetic patients in Japan according to gender, age, and geographical region: a multicenter study conducted in seven regions of Japan. Diabetol Int 2016;7:314-320. |
| 33. |
横山 宏樹, 前川 聡: JDDM：日本人糖尿病の大規模臨床・疫学研究．Diabetes Frontier vol.26 No.6, p. 713-721 , 2015． |
| 34. |
横山 宏樹, 水谷 有加利, 堀口 真恵： 血圧管理とそのコツ： 糖尿病腎症の診断と治療 Up To Date．月刊糖尿病vol. 7, No.12, p. 34-40 , 2015. |
| 35. |
Yokoyama H，Ogawa M，Honjo J，Okizaki S，Yamada D，Shudo R，Shimizu H，Sone H，Haneda M. Risk factors associated with abnormal cognition in Japanese outpatients with diabetes, hypertension or dyslipidemia. Diabetol Int 2015;6:268-274. |
| 36. |
Yokoyama H, Araki S, Watanabe S, Honjo J，Okizaki S，Yamada D，Shudo R，Shimizu H，Sone H，Haneda M. Prevalence of resistant hypertension and associated factors in Japanese subjects with type 2 diabetes. Diabetes Res Clin Pract 2015;110:18-25. |
| 37. |
Yokoyama H, Araki S, Kawai K, Hirao K, Oishi M, Sugimoto K, Sone H，Maegawa H, Kashiwagi A, on behalf of Japan Diabetes Clinical Data Management Study Group. Pioglitazone treatment and cardiovascular event and death in subjects with type 2 diabetes without established cardiovascular disease (JDDM36). Diabetes Res Clin Pract 2015;109:485-492. |
| 38. |
Otani T, Yokoyama H, Uchigata Y. Changes in the prognosis of Japanese patients who developed type 1 diabetes before the age of 30 years. Diabetes Res Clin Pract 2015;109:434-439. |
| 39. |
横山 宏樹: 糖尿病性腎症進展抑制における血糖管理の意義（保存期）:糖尿病と腎疾患2015, 腎と透析2015, vol.78増刊号, 腎と透析編集委員会編．東京, 東京医学社, p. 424-428, 2015 |
| 40. |
横山 宏樹: 各施設でのCKDチーム医療の実践：CKDチーム医療のテキスト． 海津嘉蔵 編著． 東京, 日本医事新報社, p. 74-83, 2015 |
| 41. |
Wada T, Haneda M, Furuichi K, Babazono T, Yokoyama H, Iseki K, Araki S, Ninomiya T, Hara S, Suzuki Y, Iwano M, Kusano E, Moriya T, Satoh H, Nakamura H, Shimizu M, Toyama T, Hara A, Makino H: Research Group of Diabetic Nephropathy, Ministry of Health, Labour, and Welfare of Japan. Clinical impact of albuminuria and glomerular filtration rate on renal and cardiovascular events, and all-cause mortality in Japanese patients with type 2 diabetes. Clin Exp Nephrol 2014;18:613-620. |
| 42. |
Yokoyama H，Sone H，Honjo J，Okizaki S，Yamada D，Shudo R，Shimizu H，Moriya T and Haneda M. Relationship between a Low Ankle Brachial Index and All-Cause Death and Cardiovascular Events in Subjects with and without Diabetes. J Atheroscler Thromb 2014;21:574-581. |
| 43. |
Toyoda M，Yokoyama H，Abe K，Nakamura S，Suzuki D: Predictors of response to liraglutide in Japanese type 2 diabetes: Diabetes Res Clin Pract 2014;106:451-457. |
| 44. |
Mikada A, Narita T, Yokoyama H, Yamashita R, Horikawa Y, Tsukiyama K, Yamada Y. Effects of miglitol, sitagliptin, and initial combination therapy with both on plasma incretin responses to a mixed meal and visceral fat in over-weight Japanese patients with type 2 diabetes. The MASTER randomized, controlled trial. Diabetes Res Clin Pract 2014;106:538-547. |
| 45. |
Yokoyama H、Hirao K, Yamaguchi K, Oishi M, Gendai L, Yagi N, Takamura H, Kashiwagi A, on behalf of the Japan Diabetes Clinical Data Management Study Group. Liraglutide Versus Sitagliptin in a 24-week, Multicenter, Open-label, Randomized, Parallel-group Study in Japanese Type 2 Diabetes Mellitus Patients Responding Inadequately to a Sulfonylurea and/or One or Two Other Oral Antidiabetic Drugs (JDDM 33). Japanese Clin Med 2014;5:33-41. |
| 46. |
横山 宏樹: 厳格血糖・血圧コントロールによる顕性腎症のremission. 糖尿病学2014． 門脇 孝 編． 東京, 診断と治療社, p. 94-102, 2014 |
| 47. |
横山 宏樹, Peter Rossing, 井関 邦敏, 二宮 利治, (座談会)糖尿病患者における治療戦略-心腎関連の観点から‐：糖尿病診療マスター.vol.12 No.8,S1-S7,2014 |
| 48. |
Yokoyama H, Araki S, Honjo J, Okizaki S, Yamada D, Shudo R, Shimizu H, Sone H, Moriya T, Haneda M. Association between remission of macroalbuminuria and preservation of renal function in patients with type 2 diabetes with overt proteinuria. Diabetes Care 2013;36:3227-3233. |
| 49. |
横山 宏樹: Steno-2studyからJDDMstudyへ:最新臨床糖尿病学（上）糖尿病学の最新動向，日本臨床，70巻，増刊号3，ｐ295-300，2012 |
| 50. |
Narita T, Yokoyama H, Yamashita R, Sato T, Hosoba M, Morii T, Fujita H, Tsukiyama K, Yamada Y. Comparisons of the effects of 12-week administration of miglitol and voglibose on the responses of plasma incretins after a mixed meal in Japanese type 2 diabetic patients. Diabetes Obes Metab 2012;14:283-287. |
|
